Non-Opioid Pain Treatment Market size was valued at USD 622.5 Million in 2023 and the total revenue is expected to grow at a CAGR of 3.2% from 2024 to 2030, reaching nearly USD 776.06 Million in 2030 The escalating incidence of chronic pain conditions like arthritis and neuropathic pain amplifies the demand for non-opioid treatments. For instance, the prevalence of chronic pain among adults in the US surged, prompting a shift towards non-opioid alternatives such as physical therapy and NSAIDs. Technological advancements play a proviral role, in introducing innovative drug delivery systems and minimally invasive procedures like wearable pain management devices and neuromodulation techniques. Moreover, government initiatives aimed at curbing opioid abuse and promoting non-opioid treatments fuel Non-Opioid Pain Treatment Market expansion by mandating exploration into these options. Growing awareness among healthcare providers and patients regarding the adverse effects of opioids further steers preferences towards non-opioid solutions. Robust investments in research and development efforts by pharmaceutical companies and research institutions drive the expansion of novel non-opioid therapies, including cannabinoid-based medications and non-pharmacological interventions. Patient preference for non-addictive options, the expansion of alternative therapies, collaborations among industry players, the increasing geriatric population, and favorable healthcare reimbursement policies collectively contribute to the burgeoning growth of the Non-Opioid Pain Treatment Market, signaling a shift toward safer and more effective pain management strategies.To know about the Research Methodology:-Request Free Sample Report The Non-Opioid Pain Treatment Market is pivotal due to chronic pain affecting 100 million+ Americans, incurring a $600+ billion economic burden. Amidst a US opioid epidemic, heightened opioid use in managing chronic pain necessitates exploring interprofessional care's role. This approach highlights non-opioid alternatives like medications, physical therapy, exercise, injections, and neuromodulation. Emphasizing an individualized multimodal treatment plan based on a biopsychosocial model is crucial. This review underscores the Non-Opioid Pain Treatment Market's significance in managing chronic pain by shifting focus toward diversified non-opioid pain treatments amidst the escalating concerns linked to opioid usage in the United States. AmacaThera secured C$4 million ($2.94 million) in a Series A extension funding led by Paul Austin, aiming to advance AMT-143, a non-opioid therapy for post-surgery pain. Existing investors like Inveready, Lumira Ventures, MaRS IAF, StandUp Ventures, and Women in Technology Venture Fund also participated. The funding enables the clinical development of AMT-143, utilizing AmacaThera's AmacaGel platform technology. AMT-143 offers prolonged pain relief with quicker onset and sustained control for up to three days, potentially reducing post-surgery opioid usage. The focus extends to pipeline programs targeting the injectable, local, and sustained-release Non-Opioid Pain Treatment Market, signifying a significant leap in post-surgery pain management innovation.
Non-Opioid Pain Treatment Market Dynamics:
Rising Awareness and Non-Opioid Uptake Catalysts for Non-Opioid Pain Treatment Market Growth Rising awareness surrounding the dangers of opioid usage acts as a catalyst for the market's expansion. Additionally, it is estimated that 54.6% of adults with chronic pain only used nonopioid pain management techniques. Heightened concerns about the opioid epidemic prompt a shift towards safer non-opioid alternatives. Technological advancements in drug delivery systems and neurostimulation devices further propel Non-Opioid Pain Treatment Market growth by offering innovative non-opioid solutions. Government initiatives and stringent regulations mandating non-opioid pain management strategies amplify Non-Opioid Pain Treatment market demand, supported by Medicare's incentivization of these therapies. The increasing prevalence of chronic pain conditions, particularly ailments like arthritis and lower back pain, fuels the need for effective non-opioid treatments. Collaborations among pharmaceutical firms, research institutions, and healthcare providers drive innovation, exemplified by strategic partnerships like Pfizer and Eli Lilly's joint efforts in non-opioid pain therapies. With a growing geriatric population seeking safer pain management solutions, investments in R&D by pharmaceutical companies, such as Grünenthal's focus on novel non-opioid analgesics, underscore the Non-Opioid Pain Treatment Market potential. Patient preference for non-addictive options and the expansion of alternative therapies like acupuncture and mindfulness-based interventions contribute to market growth. Additionally, supportive healthcare reimbursement policies advocating non-opioid treatments encourage their adoption, fostering Non-Opioid Pain Treatment Market growth by both providers and patients. These drivers collectively fuel the growth trajectory of the Non-Opioid Pain Treatment Market, positioning it as a pivotal sector within the healthcare industry. Tanezumab and VX-548 Advancing Non-Addictive Pain Treatments Propel Non-Opioid Pain Treatment Market Growth Apart from existing medications, the pharmaceutical industry is actively advancing new non-opioid alternatives to address pain management. Currently, there are 546 painkillers in development, with a focus on cannabinoid receptors as key targets due to their modulation of various physiological processes, including pain sensation. For instance, pharmaceutical companies and regulators are expediting novel drugs like tanezumab for chronic pain and osteoarthritis, along with Vertex Pharmaceuticals' VX-548 for postoperative pain, prioritizing access to non-addictive pain relief options. Academic researchers outside the pharmaceutical realm are also contributing to painkiller development. A newly designed opioid molecule showcased promising results in rhesus monkeys, exhibiting pain relief without affecting breathing or inducing addiction. Despite early success in animals, its transition to human use requires further advancement. Recognizing that drugs alone not comprehensively alleviate chronic pain, a holistic approach integrating various treatments are employed. Healthcare providers increasingly incorporate diverse therapies like exercise, physical therapy, and counseling into pain management strategies. The emergence of novel drugs and the growing utilization of behavioral interventions indicate the future landscape of pain treatment. These advancements offer prospects for alleviating pain without opioid dependence, potentially curbing the ongoing epidemic. This evolution aligns with the Non-Opioid Pain Treatment Market's focus, emphasizing diversified approaches to pain management beyond pharmaceuticals, aiming for safer and more comprehensive solutions.Navigating Manufacturing Challenges in Non-Opioid Pain Treatment Market Trend The Non-Opioid Pain Treatment Market encounters manufacturing and business challenges intertwined with regulatory complexities and technical intricacies. Manufacturing hurdles encompass the need for innovative drug formulation techniques that offer effective pain relief without opioid reliance. Developing these alternatives requires extensive research, hindering rapid Non-Opioid Pain Treatment Market entry. For instance, producing non-opioid analgesics with a similar efficacy to opioids poses a technical challenge due to the complex nature of pain pathways. Additionally, ensuring scalability and cost-effectiveness in production while adhering to stringent quality standards is a continuous challenge. On the business front, Non-Opioid Pain Treatment market access and reimbursement policies profoundly impact market penetration. Access barriers arise from stringent regulatory frameworks and varying reimbursement schemes across regions. Moreover, navigating intellectual property rights for novel formulations poses hurdles in business strategies and Non-Opioid Pain Treatment Market entry. Regarding chemical laws, compliance with regulations such as the U.S. Controlled Substances Act or the European Union's regulations on pain-relieving compounds significantly influences drug development and manufacturing. Stringent regulations demand rigorous testing and compliance measures, impacting production timelines and costs. For instance, adhering to guidelines under REACH in the EU for chemical substances used in pain treatment formulations necessitates extensive documentation and testing, influencing the development and production phases. These challenges underscore the multifaceted landscape within the Non-Opioid Pain Treatment Market, blending technical complexities, regulatory hurdles, and business intricacies across varied regional landscapes. Technological Innovations Boost Evolution in Pain Relief Propel the Non-Opioid Pain Treatment Market Ongoing studies exploring cannabinoids like CBD in pain management serve as a testament to this potential. Technological advancements in drug delivery systems and neurostimulation technologies form another pivotal opportunity, exemplified by wearable pain-relief devices and advancements in neuromodulation therapies such as spinal cord stimulation systems. There's a palpable rise in demand for non-addictive alternatives, reflected in the burgeoning interest in treatments like acupuncture and physical therapy. Supportive policies and regulatory shifts advocating non-opioid pain management, like the FDA's push for non-opioid drug development, present fertile ground for novel therapies. Collaborations among pharmaceutical firms and research institutions, alongside personalized medicine approaches leveraging genetic markers, promise customized pain management solutions. Educational campaigns and Non-Opioid Pain Treatment Market growth into emerging economies with evolving healthcare infrastructures, coupled with favorable reimbursement policies, collectively propel the growth trajectory of the Non-Opioid Pain Treatment Market, highlighting a landscape ripe for innovation and expansion.
Product Composition Application Medical Cannabis Cannabinoids Chronic pain conditions like neuropathy, arthritis Menthol-Containing Menthol Mild to moderate musculoskeletal pain Omega 3 Fatty Acid-Containing Omega-3 Fatty Acids Joint and inflammatory pain Botulinum Toxins Botulinum Toxin Chronic migraines, muscle spasm Capsaicin-Derived Capsaicin Neuropathic pain, nerve-related pain Non-Opioid Pain Treatment Market Segment Analysis:
Based on drug class, the market has been segmented into NSAIDs, Acetaminophen, Local Anesthetics, and Others. Among these, the NSAIDs sub-segment is projected to generate the maximum revenue. The NSAIDs sub-segment witnessed the highest market share in the global Non-Opioid Pain Treatment Market in 2023. NSAIDs, short for Non-Steroidal Anti-Inflammatory Drugs, constitute a prominent drug class renowned for their efficacy in managing pain, inflammation, and fever. These medications play a crucial role in various medical scenarios, predominantly in alleviating mild to moderate pain stemming from conditions like arthritis, menstrual cramps, headaches, and musculoskeletal injuries. Their anti-inflammatory properties make them valuable in reducing swelling and inflammation caused by various conditions, including arthritis and soft tissue injuries. Additionally, NSAIDs are often utilized post-surgery to manage pain and aid in recovery. They function by inhibiting cyclooxygenase (COX) enzymes, thereby curbing the production of prostaglandins responsible for pain and inflammation. Their widespread availability over-the-counter and in prescription forms makes NSAIDs accessible for diverse applications which propels the growth of Non-Opioid Pain Treatment Market.Non-Opioid Pain Treatment Market Regional Analysis:
North America dominates the non- opioid pain treatment market due to growing clinical trials and increasing funding by the government. The landscape of non-opioid pain treatment continues to evolve with groundbreaking advancements that offer promising alternatives for chronic pain management. The recent FDA approval of NerveBloc, a non-opioid spray, marks a significant milestone in pain relief. This innovative solution operates by intercepting pain signals at their source, providing relief for individuals suffering from chronic neuropathic pain without the inherent risks of addiction associated with opioid medications. Complementing such innovations are the developments in spinal cord stimulators, offering targeted electrical pulses to the spinal cord. These implants present an effective approach in managing chronic pain, particularly in the back and limbs, providing patients with precise and personalized relief. Moreover, there's a noteworthy surge in the adoption of cognitive-behavioral therapy (CBT), a non-pharmacological approach gaining immense popularity in pain management. CBT equips patients with crucial pain management skills, empowering them to navigate and cope with their pain effectively, thereby reducing reliance on opioid medications. Collectively, these advancements signify a transformative shift in non-opioid pain treatment market trend, offering diversified and comprehensive solutions to address chronic pain while mitigating the risks associated with opioid use. 1. National Initiatives: The National Institutes of Health (NIH) spearheads the Helping to End Addiction Long-term Initiative (HEAL), allocating millions to non-opioid pain research and development. 2. Policy Push: Regulatory bodies like the Centers for Disease Control and Prevention (CDC) advocate for non-opioid alternatives, influencing prescribing practices and insurance coverage. 3. Veteran Focus: Programs like the Department of Veterans Affairs' Pain Management Initiative prioritize non-opioid options for veterans, a high-risk group for opioid misuse.Global Non-Opioid Pain Treatment Market Scope: Inquire before buying
Global Non-Opioid Pain Treatment Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 622.5 Mn. Forecast Period 2024 to 2030 CAGR: 3.2% Market Size in 2030: US $ 776.06 Mn. Segments Covered: by Drug Class NSAIDs Acetaminophen Local Anesthetics Others by Pain Type Chronic Pain Post-operative Pain Cancer Pain Others by Route of Administration Oral Injectable Topical Others by Distribution Channel Hospital Pharmacy Retail Pharmacy Others Non-Opioid Pain Treatment Market by Region:
North America (United States, Canada, and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A) South America (Brazil, Argentina Rest of South America)Non-Opioid Pain Treatment Market Leading Key Players
North America: 1. Regeneron Pharmaceuticals Inc. (U.S.) 2. Eli Lilly and company (U.S.) 3. Centrexion Therapeutics Corp. (U.S.) 4. Acorda Therapeutics (U.S.) 5. Biogen (U.S.) 6. VM Biotech (U.S.) 7. Novartis AG (Switzerland) 8. Alder Biopharmaceuticals (U.S.) 9. Pfizer Inc. (U.S.) 10. Clarion (U.S.) 11. Veridian Healthcare (U.S.) 12. Sorrento Therapeutics, Inc. (U.S.) Europe: 13. GSK plc. (U.K.) 14. Sanofi (France) 15. Endo Pharmaceuticals (Ireland) Asia Pacific: 16. Hisamitsu Pharmaceutical Co., Inc. (Japan) 17. TEH SENG PHARMACEUTICAL MFG. CO., LTD. (Taiwan) 18. Teikoku Seiyaku Co. Ltd. (Japan) Middle East and Africa: 19. Teva Pharmaceutical Industries Ltd. (Israel) FAQ: 1] Which region is expected to hold the highest share in the Market ? Ans. The North American region is expected to hold the highest share in the Market . 2] Who are the top key players in the Market ? Ans. GSK plc. (U.K.), Sanofi (France), and Endo Pharmaceuticals (Ireland)are the top key players in the Market. 3] Which segment is expected to hold the largest market share in the Market by 2030? Ans. The drug type segment is expected to hold the largest market share in the Market by 2030. 4] What is the market size of the Non-Opioid Pain Treatment Market by 2023? Ans. The market size of the Non-Opioid Pain Treatment Market is expected to reach USD 622.5 Million by 2023. 5] What was the market size of the Non-Opioid Pain Treatment Market in 2030? Ans. The market size of the Non-Opioid Pain Treatment Market was worth USD 776.06 Million in 2030.
1. Non-Opioid Pain Treatment Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Non-Opioid Pain Treatment Market: Dynamics 2.1. Market Trends by Region 2.1.1. North America 2.1.2. Europe 2.1.3. Asia Pacific 2.1.4. Middle East and Africa 2.1.5. South America 2.2. Market Dynamics by Region 2.2.1. North America 2.2.1.1. Drivers 2.2.1.2. Restraints 2.2.1.3. Opportunities 2.2.1.4. Challenges 2.2.2. Europe 2.2.2.1. Drivers 2.2.2.2. Restraints 2.2.2.3. Opportunities 2.2.2.4. Challenges 2.2.3. Asia Pacific 2.2.3.1. Drivers 2.2.3.2. Restraints 2.2.3.3. Opportunities 2.2.3.4. Challenges 2.2.4. Middle East and Africa 2.2.4.1. Drivers 2.2.4.2. Restraints 2.2.4.3. Opportunities 2.2.4.4. Challenges 2.2.5. South America 2.2.5.1. Drivers 2.2.5.2. Restraints 2.2.5.3. Opportunities 2.2.5.4. Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Value Chain Analysis 2.6. Technological Roadmap 2.7. Regulatory Landscape by Region 2.7.1. North America 2.7.2. Europe 2.7.3. Asia Pacific 2.7.4. Middle East and Africa 2.7.5. South America 2.8. Analysis of Government Schemes and Initiatives for Non-Opioid Pain Treatment Industry 2.9. Key Opinion Leader Analysis 2.10. The Global Pandemic Impact on Non-Opioid Pain Treatment Market 3. Non-Opioid Pain Treatment Market: Global Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 3.1. Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 3.1.1. NSAIDs 3.1.2. Acetaminophen 3.1.3. Local Anesthetics 3.1.4. Others 3.2. Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 3.2.1. Chronic Pain 3.2.2. Post-operative Pain 3.2.3. Cancer Pain 3.2.4. Others 3.3. Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 3.3.1. Oral 3.3.2. Injectable 3.3.3. Topical 3.3.4. Others 3.4. Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 3.4.1. Hospital Pharmacy 3.4.2. Retail Pharmacy 3.4.3. Others 3.5. Non-Opioid Pain Treatment Market Size and Forecast, By Region (2023-2030) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Non-Opioid Pain Treatment Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 4.1. North America Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 4.1.1. NSAIDs 4.1.2. Acetaminophen 4.1.3. Local Anesthetics 4.1.4. Others 4.2. North America Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 4.2.1. Chronic Pain 4.2.2. Post-operative Pain 4.2.3. Cancer Pain 4.2.4. Others 4.3. North America Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 4.3.1. Oral 4.3.2. Injectable 4.3.3. Topical 4.3.4. Others 4.4. North America Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 4.4.1. Hospital Pharmacy 4.4.2. Retail Pharmacy 4.4.3. Others 4.5. North America Non-Opioid Pain Treatment Market Size and Forecast, by Country (2023-2030) 4.5.1. United States 4.5.1.1. United States Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 4.5.1.1.1. NSAIDs 4.5.1.1.2. Acetaminophen 4.5.1.1.3. Local Anesthetics 4.5.1.1.4. Others 4.5.1.2. United States Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 4.5.1.2.1. Chronic Pain 4.5.1.2.2. Post-operative Pain 4.5.1.2.3. Cancer Pain 4.5.1.2.4. Others 4.5.1.3. United States Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 4.5.1.3.1. Oral 4.5.1.3.2. Injectable 4.5.1.3.3. Topical 4.5.1.3.4. Others 4.5.1.3.5. Others 4.5.1.4. United States Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 4.5.1.4.1. Hospital Pharmacy 4.5.1.4.2. Retail Pharmacy 4.5.1.4.3. Others 4.5.2. Canada 4.5.2.1. Canada Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 4.5.2.1.1. NSAIDs 4.5.2.1.2. Acetaminophen 4.5.2.1.3. Local Anesthetics 4.5.2.1.4. Others 4.5.2.2. Canada Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 4.5.2.2.1. Chronic Pain 4.5.2.2.2. Post-operative Pain 4.5.2.2.3. Cancer Pain 4.5.2.2.4. Others 4.5.2.3. Canada Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 4.5.2.3.1. Oral 4.5.2.3.2. Injectable 4.5.2.3.3. Topical 4.5.2.3.4. Others 4.5.2.4. Canada Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 4.5.2.4.1. Hospital Pharmacy 4.5.2.4.2. Retail Pharmacy 4.5.2.4.3. Others 4.5.3. Mexico 4.5.3.1. Mexico Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 4.5.3.1.1. NSAIDs 4.5.3.1.2. Acetaminophen 4.5.3.1.3. Local Anesthetics 4.5.3.1.4. Others 4.5.3.2. Mexico Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 4.5.3.2.1. Chronic Pain 4.5.3.2.2. Post-operative Pain 4.5.3.2.3. Cancer Pain 4.5.3.2.4. Others 4.5.3.3. Mexico Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 4.5.3.3.1. Oral 4.5.3.3.2. Injectable 4.5.3.3.3. Topical 4.5.3.3.4. Others 4.5.3.4. Mexico Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 4.5.3.4.1. Hospital Pharmacy 4.5.3.4.2. Retail Pharmacy 4.5.3.4.3. Others 5. Europe Non-Opioid Pain Treatment Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 5.1. Europe Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.2. Europe Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.3. Europe Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.4. Europe Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5. Europe Non-Opioid Pain Treatment Market Size and Forecast, by Country (2023-2030) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.1.2. United Kingdom Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.1.3. United Kingdom Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.1.4. United Kingdom Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.2. France 5.5.2.1. France Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.2.2. France Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.2.3. France Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.2.4. France Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.3. Germany 5.5.3.1. Germany Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.3.2. Germany Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.3.3. Germany Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.3.4. Germany Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.4. Italy 5.5.4.1. Italy Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.4.2. Italy Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.4.3. Italy Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.4.4. Italy Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.5. Spain 5.5.5.1. Spain Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.5.2. Spain Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.5.3. Spain Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.5.4. Spain Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.6. Sweden 5.5.6.1. Sweden Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.6.2. Sweden Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.6.3. Sweden Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.6.4. Sweden Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.7. Austria 5.5.7.1. Austria Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.7.2. Austria Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.7.3. Austria Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.7.4. Austria Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 5.5.8.2. Rest of Europe Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 5.5.8.3. Rest of Europe Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 5.5.8.4. Rest of Europe Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 6.1. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.2. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.3. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.4. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5. Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, by Country (2023-2030) 6.5.1. China 6.5.1.1. China Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.1.2. China Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.1.3. China Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.1.4. China Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.2. S Korea 6.5.2.1. S Korea Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.2.2. S Korea Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.2.3. S Korea Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.2.4. S Korea Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.3. Japan 6.5.3.1. Japan Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.3.2. Japan Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.3.3. Japan Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.3.4. Japan Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.4. India 6.5.4.1. India Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.4.2. India Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.4.3. India Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.4.4. India Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.5. Australia 6.5.5.1. Australia Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.5.2. Australia Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.5.3. Australia Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.5.4. Australia Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.6. Indonesia 6.5.6.1. Indonesia Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.6.2. Indonesia Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.6.3. Indonesia Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.6.4. Indonesia Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.7. Malaysia 6.5.7.1. Malaysia Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.7.2. Malaysia Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.7.3. Malaysia Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.7.4. Malaysia Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.8. Vietnam 6.5.8.1. Vietnam Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.8.2. Vietnam Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.8.3. Vietnam Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.8.4. Vietnam Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.9. Taiwan 6.5.9.1. Taiwan Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.9.2. Taiwan Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.9.3. Taiwan Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.9.4. Taiwan Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 6.5.10.2. Rest of Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 6.5.10.3. Rest of Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 6.5.10.4. Rest of Asia Pacific Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 7. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030 7.1. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 7.2. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 7.3. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 7.4. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 7.5. Middle East and Africa Non-Opioid Pain Treatment Market Size and Forecast, by Country (2023-2030) 7.5.1. South Africa 7.5.1.1. South Africa Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 7.5.1.2. South Africa Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 7.5.1.3. South Africa Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 7.5.1.4. South Africa Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 7.5.2. GCC 7.5.2.1. GCC Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 7.5.2.2. GCC Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 7.5.2.3. GCC Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 7.5.2.4. GCC Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 7.5.3. Nigeria 7.5.3.1. Nigeria Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 7.5.3.2. Nigeria Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 7.5.3.3. Nigeria Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 7.5.3.4. Nigeria Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 7.5.4.2. Rest of ME&A Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 7.5.4.3. Rest of ME&A Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 7.5.4.4. Rest of ME&A Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 8. South America Non-Opioid Pain Treatment Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030 8.1. South America Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 8.2. South America Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 8.3. South America Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 8.4. South America Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 8.5. South America Non-Opioid Pain Treatment Market Size and Forecast, by Country (2023-2030) 8.5.1. Brazil 8.5.1.1. Brazil Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 8.5.1.2. Brazil Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 8.5.1.3. Brazil Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 8.5.1.4. Brazil Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 8.5.2. Argentina 8.5.2.1. Argentina Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 8.5.2.2. Argentina Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 8.5.2.3. Argentina Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 8.5.2.4. Argentina Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Non-Opioid Pain Treatment Market Size and Forecast, By Drug Class (2023-2030) 8.5.3.2. Rest Of South America Non-Opioid Pain Treatment Market Size and Forecast, By Pain Type (2023-2030) 8.5.3.3. Rest Of South America Non-Opioid Pain Treatment Market Size and Forecast, By Route of Administration (2023-2030) 8.5.3.4. Rest Of South America Non-Opioid Pain Treatment Market Size and Forecast, By Distribution Channel (2023-2030) 9. Global Non-Opioid Pain Treatment Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Service Segment 9.3.3. Distribution Channelr Segment 9.3.4. Revenue (2022) 9.3.5. Manufacturing Locations 9.4. Leading Non-Opioid Pain Treatment Market Companies, by Market Capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Regeneron Pharmaceuticals Inc. (U.S.) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Eli Lilly and company (U.S.) 10.3. Centrexion Therapeutics Corp. (U.S.) 10.4. Acorda Therapeutics (U.S.) 10.5. Biogen (U.S.) 10.6. VM Biotech (U.S.) 10.7. Novartis AG (Switzerland) 10.8. Alder Biopharmaceuticals (U.S.) 10.9. Pfizer Inc. (U.S.) 10.10. Clarion (U.S.) 10.11. Veridian Healthcare (U.S.) 10.12. Sorrento Therapeutics, Inc. (U.S.) 10.13. GSK plc. (U.K.) 10.14. Sanofi (France) 10.15. Endo Pharmaceuticals (Ireland) 10.16. Hisamitsu Pharmaceutical Co., Inc. (Japan) 10.17. TEH SENG PHARMACEUTICAL MFG. CO., LTD. (Taiwan) 10.18. Teikoku Seiyaku Co. Ltd. (Japan) 10.19. Teva Pharmaceutical Industries Ltd. (Israel) 11. Key Findings 12. Industry Recommendations 13. Non-Opioid Pain Treatment Market: Research Methodology.